Understand how the Growth in Spending on Medication Impacts the Economy and QR Group’s Role in Access to Health Products
In 2021, Brazilians spent R$168.3 billion on purchasing medications, representing 33.7% of household spending on healthcare, according to data from IBGE. This increase reflects both the impact of the pandemic and the aging of the population and the rise in medication prices. In the regulatory scenario, QR Group has stood out in facilitating access to innovative medications, ensuring compliance with ANVISA’s strict requirements and providing efficient solutions for international companies wishing to enter the Brazilian market.
Impacts of the Growth in Spending on Medication
The increase in spending on medications from 31.8% in 2020 to 33.7% in 2021 reflects a growing demand, driven by the pandemic and the aging population. This scenario is alarming for low-income families, such as Eva Cerqueira’s, who depend on the Farmácia Popular program to cover the costs of their medications. Subsidy programs, such as Farmácia Popular, suffered budget cuts in 2021, which intensifies the need for efficient regulation to ensure that essential medicines reach the population in an affordable way.
How QR Group Contributes to Access to Quality Medicines
QR Group, a specialist in regulatory consulting and product registration with ANVISA, plays a crucial role in the Brazilian population’s access to quality medicines. By offering the Brazilian Registration Holder (BRH) service, the company facilitates the process of registering medicines and medical devices, ensuring that international companies can operate in Brazil safely and quickly. With the increase in healthcare costs, QR Group has been an essential bridge for new medicines to be made available quickly in the country, helping to reduce the economic impact on families.
The Importance of Regulatory Services for Access to Innovative Technologies
In addition to the increase in medicine consumption, overall healthcare expenses in Brazil reached R$499.2 billion in 2021, driven by the private sector. QR Group works to eliminate regulatory obstacles that may delay the arrival of innovations in the Brazilian market, ensuring that emerging health technologies reach the population quickly. The efficiency of the regulatory process not only helps international companies establish themselves in Brazil, but also directly benefits consumers, who gain access to more modern and effective treatment options.
If you are a manufacturer of medical devices or medicines and want to expand your business in Brazil, contact QR Group to ensure an agile and hassle-free regulatory process. We are ready to help your company comply with all ANVISA requirements safely and efficiently.
Source:
UOL Notícias
Image:
Foto de Rodrigo Nunes/MS – Sobradinho (DF), 23/09/2016
